- CDI is a prevalent and concerning infection that is on the rise
- Fidaxomicin is recommended over oral vancomycin for the treatment if CDI given potential for decreased recurrence
- Oral vancomycin remains an acceptable alternative
Literature supporting adjunctive therapies, including bezlotoxumab, prophylaxis, and FMT are promising, but require additional investigation
